Healthcare Industry News: thrombosis
News Release - July 2, 2012
BG Medicine, Inc. Appoints Bill Densel, General Manager, CardioSCOREWALTHAM, Mass., July 2, 2012 -- (Healthcare Sales & Marketing Network) -- BG Medicine, Inc. (BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that Bill Densel has joined the company as General Manager, CardioSCORE. In this role, he will report to President and CEO Eric Bouvier, with overall responsibility for the development and growth of CardioSCORE, BG Medicine's diagnostic blood test designed to improve the identification of individuals at high risk for near-term major cardiovascular events such as heart and stroke. Mr. Densel brings nearly two decades of developing and commercializing breakthrough technologies in medical devices, biotechnology and diagnostics to BG Medicine. He most recently served as Chief Executive Officer of Dune Medical Devices.
"Bill is a welcome and strategically important addition to our management team," said Eric Bouvier, President and Chief Executive Officer of BG Medicine. "We believe that his proven general management experience, coupled with an extensive sales and marketing background focused on cardiology and oncology, will provide us with an ideal skill set to commercialize and build the CardioSCORE franchise, which is a key component of our product portfolio. CardioSCORE is designed to identify high risk patients who would not otherwise be identified using traditional risk scales, particularly in the near-term, and has the potential to enable optimized preventative treatment and save many lives."
Prior to Dune Medical Devices, Mr. Densel held positions of increasing responsibility at Hologic Corporation where he was Vice President of Marketing for the GYN Surgical business and Sr. Director of the Neuroscience Business Unit of Cytyc Corporation. Previously, he held roles in Strategic Planning and Market Development for Boston Scientific. Mr. Densel began his career at Snowden Pencer, a surgical instrumentation company that was acquired by Genzyme Corporation, where he held positions of increasing responsibility in sales, marketing and business development. Following his graduation from Duke University, Mr. Densel received a commission in the U.S. Navy and served for four years as a Special Operations Officer.
CardioSCORE is a diagnostic blood test designed to improve the identification of individuals at high risk for near-term major cardiovascular events, such as heart attack and stroke, over conventional risk factor scoring, in otherwise asymptomatic adults. The test is a proprietary in vitro diagnostic multivariate index assay that measures the levels of several protein biomarkers in blood and integrates the results to yield a single numerical score that is related to an individual's near-term cardiovascular risk. BG Medicine filed a 510(k) Premarket Notification with the U.S. Food and Drug Administration in December 2011 for regulatory clearance of CardioSCORE, following the successful completion of a pivotal clinical validation study.
The American Heart Association estimates that in the United States alone, more than one million people die annually from complications from atherosclerosis and atherothrombosis, and that the total annual cost of treating these conditions exceeds $360 billion.
About BG Medicine, Inc.
BG Medicine, Inc. (BGMD) is a life sciences company focused on the discovery, development, and commercialization of novel cardiovascular diagnostics to address significant unmet medical needs, improve patient outcomes and contain healthcare costs. The Company's first commercialized product, the BGM Galectin-3(TM) test for use in patients with heart failure, is available in the United States and Europe. BG Medicine is also developing CardioSCORE, a blood test designed to identify individuals at high risk for near-term major cardiovascular events, such as heart attack and stroke. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.
Safe Harbor Statements under the Private Securities Litigation Reform Act of 1995: Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. Forward- looking statements in this news release may address the following subjects, among others: our expectations concerning our belief that CardioSCORE may improve the identification of individuals at high risk for near-term major cardiovascular events over conventional risk factor scoring; our expectations for the market potential of CardioSCORE; our expectation that the FDA will provide regulatory clearance for our CardioSCORE test; and our beliefs regarding expected contributions from our new General Manager. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our recent filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward- looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Source: BG Medicine
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.